PMID- 18698545
OWN - NLM
STAT- MEDLINE
DCOM- 20081104
LR  - 20181201
IS  - 1898-018X (Electronic)
IS  - 1898-018X (Linking)
VI  - 15
IP  - 4
DP  - 2008
TI  - The influence of low dose atorvastatin on inflammatory marker levels in patients 
      with acute coronary syndrome and its potential clinical value.
PG  - 357-64
AB  - BACKGROUND: High-dose statins are used in acute coronary syndromes (ACS) to 
      reduce inflammation. The aim of the study was the evaluation of the influence of 
      low-dose atorvastatin (20 mg) on selected inflammatory parameters and clinical 
      outcomes after ACS. METHODS: Seventy eight patients (pts) with ACS were randomly 
      divided into group A (39 pts) taking atorvastatin, and group NA (39 pts) not 
      taking any statin for the following six weeks. C-reactive protein (CRP), 
      interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and tumour 
      necrosis factor alpha (TNFa) levels were measured on the first and the fifth days 
      and six weeks after ACS. RESULTS: There was no significant CRP and IL-6 level 
      decrease in group A (CRP--62%; IL-6-73%) or group NA (CRP-44%; IL-6-62%). There 
      was also no significant change in TNFa levels. The MCP-1 level finally reached 
      the level of significant difference (p < 0.04). Cardiovascular events (MACE) and 
      the restenosis rates did not differ between the groups. CONCLUSIONS: Low-dose 
      atorvastatin does not have a significant influence on cooling down inflammation 
      in ACS, and MCP-1 can be used as an early indicator of statin anti-inflammatory 
      activity. Furthermore, it does not reduce MACE or restenosis rates despite its 
      influence on MCP-1 levels.
FAU - Lewandowski, Maciej
AU  - Lewandowski M
AD  - Clinic of Cardiology, Medical University, Szczecin, Poland. malewandowski@o2.pl
FAU - Kornacewicz-Jach, Zdzislawa
AU  - Kornacewicz-Jach Z
FAU - Millo, Barbara
AU  - Millo B
FAU - Zielonka, Joanna
AU  - Zielonka J
FAU - Czechowska, Malgorzata
AU  - Czechowska M
FAU - Kaliszczak, Robert
AU  - Kaliszczak R
FAU - Plonska, Edyta
AU  - Plonska E
FAU - Goracy, Jaroslaw
AU  - Goracy J
FAU - Kazmierczak, Jaroslaw
AU  - Kazmierczak J
FAU - Naruszewicz, Marek
AU  - Naruszewicz M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Poland
TA  - Cardiol J
JT  - Cardiology journal
JID - 101392712
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Interleukin-6)
RN  - 0 (Pyrroles)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - A0JWA85V8F (Atorvastatin)
SB  - IM
MH  - Acute Coronary Syndrome/*diagnosis/*drug therapy
MH  - Anticholesteremic Agents/*administration & dosage
MH  - Atorvastatin
MH  - C-Reactive Protein/analysis
MH  - Chemokine CCL2/blood
MH  - Coronary Angiography
MH  - Coronary Restenosis/diagnosis/epidemiology
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Heptanoic Acids/*administration & dosage
MH  - Humans
MH  - Inflammation Mediators/*blood
MH  - Interleukin-6/blood
MH  - Male
MH  - Middle Aged
MH  - Probability
MH  - Pyrroles/*administration & dosage
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Statistics, Nonparametric
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/blood
EDAT- 2008/08/14 09:00
MHDA- 2008/11/05 09:00
CRDT- 2008/08/14 09:00
PHST- 2008/08/14 09:00 [pubmed]
PHST- 2008/11/05 09:00 [medline]
PHST- 2008/08/14 09:00 [entrez]
PST - ppublish
SO  - Cardiol J. 2008;15(4):357-64.